Trade Biora Therapeutics Inc. - BIOR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0632 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.5684 |
| Open | 1.6184 |
| 1-Year Change | 22.49% |
| Day's Range | 1.5684 - 1.6784 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | 1.6184 | 0.0000 | 0.00% | 1.6184 | 1.6784 | 1.5684 |
| Nov 21, 2024 | 1.5684 | 0.0100 | 0.64% | 1.5584 | 1.6484 | 1.5184 |
| Nov 20, 2024 | 1.6184 | 0.0500 | 3.19% | 1.5684 | 1.6784 | 1.4184 |
| Nov 19, 2024 | 1.6084 | -0.1300 | -7.48% | 1.7384 | 1.8184 | 1.5384 |
| Nov 18, 2024 | 1.7984 | -0.2300 | -11.34% | 2.0284 | 2.0284 | 1.7484 |
| Nov 15, 2024 | 2.0984 | -0.3700 | -14.99% | 2.4684 | 2.4684 | 2.0084 |
| Nov 14, 2024 | 2.3684 | -0.1200 | -4.82% | 2.4884 | 2.4884 | 2.2984 |
| Nov 13, 2024 | 2.4484 | -0.1600 | -6.13% | 2.6084 | 2.7384 | 2.4084 |
| Nov 12, 2024 | 2.6184 | -0.2300 | -8.07% | 2.8484 | 3.0184 | 2.5684 |
| Nov 11, 2024 | 2.7184 | -0.0200 | -0.73% | 2.7384 | 2.9784 | 2.6584 |
| Nov 8, 2024 | 2.5384 | -0.0700 | -2.68% | 2.6084 | 2.6484 | 2.4384 |
| Nov 7, 2024 | 2.6384 | -0.0700 | -2.58% | 2.7084 | 2.7984 | 2.5984 |
| Nov 6, 2024 | 2.8284 | -0.0300 | -1.05% | 2.8584 | 2.9384 | 2.5484 |
| Nov 5, 2024 | 2.7484 | -0.0500 | -1.79% | 2.7984 | 2.8384 | 2.2984 |
| Nov 4, 2024 | 2.8984 | -0.4000 | -12.13% | 3.2984 | 3.3084 | 2.7684 |
| Nov 1, 2024 | 3.2984 | -0.0100 | -0.30% | 3.3084 | 3.4284 | 3.2984 |
| Oct 31, 2024 | 3.3884 | -0.0600 | -1.74% | 3.4484 | 3.4784 | 3.3084 |
| Oct 30, 2024 | 3.4484 | -0.1000 | -2.82% | 3.5484 | 3.5484 | 3.3484 |
| Oct 29, 2024 | 3.4784 | -0.2800 | -7.45% | 3.7584 | 3.8184 | 3.3984 |
| Oct 28, 2024 | 4.3584 | 0.0900 | 2.11% | 4.2684 | 4.3984 | 3.9984 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Biora Therapeutics Inc. Company profile
Progenity (PROG)/Biora Therapeutics (BIOR) is a biotechnology firm focused on the development of oral biotherapeutics. Founded in 2010, the company creates drug-device combinations that enable new therapeutic delivery methods in two main areas:
Targeted delivery of therapeutics to the site of disease in the gastrointestinal (GI) tract, to improve outcomes for patients with Inflammatory Bowel Disease (IBD)
Systemic biotherapeutic delivery, which is intended to replace injection with needle-free, oral delivery technology
Progenity is also working on diagnostic tools to help characterise the GI tract and diagnose GI diseases such as Small Intestine Bacterial Overgrowth (SIBO). The technologies can pinpoint the location of the disease.
Prior to June 2021, the San Diego, California-based company focused on the prenatal carrier screening and non-invasive prenatal test market. It targeted preconception planning and routine pregnancy management for genetic disease risk assessment.
The company’s operations included anatomic and molecular pathology testing products under an affiliate, Avero Diagnostics.
A former affiliate, Mattison Pathology, a Texas firm trading as Avero Diagnostics, expanded the company’s operations to include anatomic and molecular pathology testing products.
The company also operated a certified laboratory in Michigan that specialised in the molecular testing markets serving women’s health providers in the obstetric, gynaecological, fertility, and maternal foetal medicine speciality areas in the US.
In June 2021, Progenity announced a strategic transformation which included closing the Progenity genetics lab in Ann Arbor, Michigan. It sold the Avero laboratory business in December 2021 as part of the transformation.
On 12 April 2022, Progenity announced it would change its name to Biora Therapeuctics in the second quarter of 2022. The strategy aims to better reflect its focus of developing targeted and systemic oral delivery of biotherapeutics.
The company will also change its stock symbol on the Nasdaq from PROG to BIOR. Progenity went public on 19 June 2020.
| Industry: | Bio Therapeutic Drugs |
4330 La Jolla Village Drive
Suite 200
SAN DIEGO
CALIFORNIA 92122
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com